Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 study of lurasidone versus risperidone in clinically stable adults with schizophrenia
ISRCTN97049967Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- May 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lurasidone and risperidone in schizophrenia (3 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Long-term safety and tolerability at 12 months and Safety follow-up at 18 months. Started May 2008; status: completed.
02
Drugs
lurasidonerisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ISRCTN97049967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN97049967.